PuSH - Publikationsserver des Helmholtz Zentrums München

Rajić, S.* ; Delerue, T. ; Ronkainen, J.* ; Zhang, R.* ; Ciantar, J.* ; Kostiniuk, D.* ; Mishra, P.P.* ; Lyytikäinen, L.P.* ; Mononen, N.* ; Kananen, L.* ; Peters, A. ; Winkelmann, J. ; Kleber, M.E.* ; Lorkowski, S.* ; Kähönen, M.* ; Lehtimäki, T.* ; Raitakari, O.* ; Waldenberger, M. ; Gieger, C. ; März, W.* ; Harville, E.W.* ; Sebert, S.* ; Marttila, S.* ; Raitoharju, E.*

Regulation of nc886 (vtRNA2-1) RNAs is associated with cardiometabolic risk factors and diseases.

Clin. Epigenet. 17:68 (2025)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Non-coding 886 (nc886, vtRNA2-1) is a polymorphically imprinted gene. The methylation status of this locus has been shown to be associated with periconceptional conditions, and both the methylation status and the levels of nc886 RNAs have been shown to associate with later-life health traits. We have previously shown that nc886 RNA levels are associated not only with the methylation status of the locus, but also with a genetic polymorphism upstream from the locus. In this study, we describe the genetic and epigenetic regulators that predict lifelong nc886 RNA levels, as well as their association with cardiometabolic disease (CMD) risk factors and events. We utilised six population cohorts and one CMD cohort comprising 9058 individuals in total. The association of nc886 RNA levels, as predicted by epigenetic and genetic regulators, with CMD phenotypes was analysed using regression models, with a meta-analysis of the results. The meta-analysis showed that individuals with upregulated nc886 RNA levels have higher diastolic blood pressure (β = 0.07, p = 0.008), lower HDL levels (β =  - 0.07, p = 0.006) and an increased incidence of type 2 diabetes (OR = 1.260, p = 0.013). Moreover, CMD patients with upregulated nc886 RNA levels have an increased incidence of stroke (OR = 1.581, p = 0.006) and death (OR = 1.290, p = 0.046). In conclusion, we show that individuals who are predicted to present elevated nc886 RNA levels have poorer cardiovascular health and are at an elevated risk of complications in secondary prevention. This unique mechanism yields metabolic variation in human populations, constituting a CMD risk factor that cannot be modified through lifestyle choices.
Impact Factor
Scopus SNIP
Altmetric
4.400
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cardiometabolic Disease ; Dna Methylation ; Imprinted Gene ; Nc886 ; Vtrna2-1; Dna Methylation; Cohort Profile; Loci; Epigenetics; Expression; Genetics; Pkr
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 1868-7075
e-ISSN 1868-7083
Zeitschrift Clinical Epigenetics
Quellenangaben Band: 17, Heft: 1, Seiten: , Artikelnummer: 68 Supplement: ,
Verlag Springer
Verlagsort Berlin : Heidelberg
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Epidemiology (EPI)
Institute of Neurogenomics (ING)
POF Topic(s) 30202 - Environmental Health
30205 - Bioengineering and Digital Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-504091-001
G-504000-010
G-503200-001
G-504091-004
Förderungen Tampere University (including Tampere University Hospital)
Scopus ID 105003873483
PubMed ID 40301926
Erfassungsdatum 2025-05-11